EP0907659A1 - Synthetic inhibitors of hepatitis c virus ns3 protease - Google Patents

Synthetic inhibitors of hepatitis c virus ns3 protease

Info

Publication number
EP0907659A1
EP0907659A1 EP97923563A EP97923563A EP0907659A1 EP 0907659 A1 EP0907659 A1 EP 0907659A1 EP 97923563 A EP97923563 A EP 97923563A EP 97923563 A EP97923563 A EP 97923563A EP 0907659 A1 EP0907659 A1 EP 0907659A1
Authority
EP
European Patent Office
Prior art keywords
seq
val
peptide
subsequence
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97923563A
Other languages
German (de)
French (fr)
Inventor
Rumin Zhang
Philip W. Mui
Patricia C. Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0907659A1 publication Critical patent/EP0907659A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • Hepatitis C virus is considered to be the major etiological agent of non-A non-B (NANB) hepatitis, chronic liver disease, and hepatocellular carcinoma (HCC) around the world.
  • NANB non-A non-B
  • HCC hepatocellular carcinoma
  • the viral infection accounts for greater than 90% of transfusion -associated hepatitis in U.S. and it is the predominant form of hepatitis in adults over 40 years of age. Almost all of the infections result in chronic hepatitis and nearly 20% develop liver cirrhosis.
  • the virus particle has not been identified due to the lack of an efficient in vitro replication system and the extremely low amount of HCV particles in infected liver tissues or blood.
  • molecular cloning of the viral genome has been accomplished by isolating the messenger RNA (mRNA) from the serum of infected chimpanzees then cloned using recombinant methodologies.
  • mRNA messenger RNA
  • HCV contains a positive strand RNA genome comprising approximately 9400 nucleotides, whose organization is similar to that of f la vi viruses and pestiviruses.
  • the genome of HCV like that of flavi- and pestiviruses, encodes a single large polyprotein of about 3000 amino acids which undergoes proteolysis to form mature viral proteins in infected cells.
  • HCV polyprotein is processed by cellular and viral proteases to produce the putative structural and nonstructural (NS) proteins.
  • At least nine mature viral proteins are produced from the polyprotein by specific proteolysis.
  • the order and nomenclature of the cleavage products are as follows: NH 2 -C-El-E2-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH.
  • C capsid
  • El two envelope glycoproteins
  • the host enzyme is also responsible for generating the amino terminus of NS2 .
  • the proteolytic processing of the nonstructural proteins are carried out by the viral proteases: NS2-3 and NS3, contained within the viral polyprotein.
  • the NS2-3 protease catalyzes the cleavage between NS2 and NS3. It is a metalloprotease and requires both NS2 and the protease domain of NS3.
  • the NS3 protease catalyzes the rest of the cleavages of the substrates in the nonstructural part of the polyprotein.
  • the NS3 protein contains 631 amino acid residues and is comprised of two enzymatic domains: the protease domain contained within amino acid residues 1-181 and a helicase ATPase domain contained within the rest of the protein. It is not known if the 70 kD NS3 protein is cleaved further in infected cells to separate the protease domain from the helicase domain, however, no cleavage has been observed in cell culture expression studies.
  • the NS3 protease is a member of the serine proteinase class of enzymes. It contains His, Asp, and Ser as the catalytic triad. Mutation of the catalytic triad residues abolishes the cleavages at substrates NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B.
  • the cleavage between NS3 and NS4A is mediated through an intramolecular enzymatic reaction, whereas the cleavages at NS4A/4B, 4B/5A, 5A/5B sites occur in a trans enzymatic reaction.
  • NS polyproteins in mammalian cells have established that the NS3 serine protease is necessary but not sufficient for efficient processing of all these cleavages.
  • the HCV NS3 protease also requires a cofactor to catalyze some of these cleavage reactions.
  • the NS4A protein is absolutely required for the cleavage of the substrate at the NS3/4A and 4B/5A sites and increases the efficiency of cleavage of the substrate between 5A/5B, and possibly 4A/4B.
  • the HCV NS3 protease cleaves the non-structural HCV proteins which are necessary for the HCV replication, the NS3 protease can be a target for the development of therapeutic agents against the HCV virus. Thus there is a need for the development of inhibitors of the HCV protease.
  • the present invention fills this need by providing for a bivalent inhibitor of an hepatitis C NS3 protease comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide.
  • the present application further provides for an inhibitor of an HCV protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence, or a mutated full-length sequence of a substrate of the HCV NS3 protease.
  • the present application further provides for an inhibitor of an HCV NS3 protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of an HCV NS4A polypeptide.
  • the present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full- length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide.
  • the present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.
  • the present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of an HCV NS4A polypeptide.
  • the present invention further comprises a pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being an inhibitor of an HCV NS3 protease, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide, and a pharmaceutical carrier.
  • a pharmaceutical composition for treating an individual infected with hepatitis C virus said pharmaceutical composition being an inhibitor of an HCV NS3 protease, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated
  • the present invention further provides for a pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, said inhibitor being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.
  • the present invention further provides for a pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, wherein said inhibitor is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length subsequence of an HCV NS4A polypeptide.
  • Figure 1 schematically depicts an embodiment of a bivalent inhibitor of the present invention.
  • Figure 2 depicts the recombinant synthesis of plasmid pBJ1015.
  • Figure 3 depicts the recombinant synthesis of plasmid pTS56-9.
  • Figure 4 depicts the recombinant synthesis of plasmid pJB1006.
  • Figure 5 depicts the recombinant synthesis of plasmid pBJ1022.
  • Figure 6 depicts the recombinant synthesis of plasmid pNB(-V)182 ⁇ 4AHT.
  • Figure 7 depicts the recombinant synthesis of plasmid pT5His/HIV/183.
  • the present invention are inhibitors of the HCV NS3 protease.
  • the present invention relates to inhibitors of the HCV NS3 protease which inhibit either the interaction of a substrate or cofactor NS4A with the NS3 protease or a bivalent inhibitor which inhibits the interaction of the NS3 protease with both cofactor NS4A and a substrate of the NS3 protease.
  • bivalent enzyme inhibitors may provide additional advantages in terms of higher binding affinity (potency), as well as enhanced specificity against similar cellular host enzymes for reduced toxicity effects.
  • the basic strategy for the design of bivalent inhibitors of HCV NS3 protease involved the devise of a molecular framework consisting of three individual components: 1. a region appropriate for binding to a substrate binding site;
  • Figure 1 Schematically, this is represented by Figure 1 in which the substrate subsequence is depicted as block, 10, being attached to linker 12, and said linker 12 being attached to the polypeptide NS4A designated 14.
  • a substrate inhibitor which is a subsequence of the inhibitor should be a subsequence which is prior to or after the cleavage site but preferably should not contain the cleavage site.
  • a mutated subsequence or mutated full-length sequence of the substrate can be used if the cleavage site is mutated so that the cleavage of the substrate does not occur cleavage leads to mechanism-based inactivation of the protease.
  • the NS3/4A cleavage site contains the following sequence:
  • the cleavage site is between the threonine at position 10 and the serine at position 11.
  • Any subsequence inhibitor should preferably be before the serine or after the threonine residue.
  • a mutated subsequence or sequence can be produced by changing the threonine /serine cleavage site at position 10-11 to eliminate the cleavage site.
  • NS4A/4B contains the following sequence.
  • the cleavage site is between the cysteine residue at position 10 and the serine at position 11. Any subsequence should preferably be before the serine or after the cysteine, but should preferably not contain both the cysteine and the serine. Alternatively, a mutated subsequence or sequence can be produced by changing the cysteine /serine cleavage site at position 10 - 11 to eliminate the cleavage site.
  • NS4B/5A contains the following sequence.
  • Trp He Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu 5 10 15
  • the cleavage site is between the cysteine at position 10 and serine at position 11. Any subsequence should preferably end before the serine or start after the cysteine but should preferably not contain both the serine and the cysteine. Alternatively, a mutated subsequence or sequence can be produced by changing the cysteine /serine cleavage sit at position 10 - 11 to eliminate the cleavage site.
  • NS5A/5B contains the following sequence. Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr
  • the cleavage site is between the cysteine at position 8 and the serine at position 9. Any subsequence should preferably end at the cysteine or start at the serine, but should preferably not contain both the cysteine and the serine. Alternatively, a mutated sequence or subsequence can be produced by changing the cysteine /serine cleavage site at position 8 - 9 to eliminate the cleavage site.
  • Linker 12 can be any chemical entity that can form a bond with polypeptides 10 and 14. Preferably the linker should be equivalent in length to a carbon chain having about 7-14 carbon residues. Examples of suitable linkers are two 6-aminocaproic acid (Acp) residues or an Acp and Lys wherein one of the polypeptides 10 or 14 form a peptide bond with the ⁇ amine of lysine.
  • bivalent inhibitors of the present invention are the following:
  • Xaa is a lysine residue having a peptide bond between its ⁇ -amino and the carboxyl group of the following lysine which forms a peptide bond with the glycine at position 10.
  • the glutamic acid residue at position 1 may or may not be acety lated.
  • Xaa is Lysine having a peptide bond between its ⁇ -amino and the carboxyl group of the following lysine which forms a peptide bond with the Gly; furthermore, the carboxyl group of the Xaa forms a peptide bond with the ⁇ -amino group of another lysine (not shown);
  • Glu-Asp-Val-Val-Cys-Cys-Acp-Acp-Lys-Gly-Ser-Leu-Val- Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO: 5) wherein the amino acids at positions 9-21 are preferably D-amino acids;
  • the lysine residue at position 8 has a peptide bond between the carboxyl of Acp and the ⁇ amino group of the lysine, and the ⁇ amino group of the lysine at position 8 forms a peptide bond with the carboxyl group of the cysteine residue at position 9 and the amino acid residues at positions 9-21 are preferably D-amino acid residues;
  • amino acid residues at positions 8-20 are preferably D- amino acid residues
  • Xaa is a Lys which forms a peptide bond between its ⁇ - amino acid and the carboxyl group of the Cys residue at position 8 and the carboxyl group of the Lys residue forms a peptide bond with an alpha amino group of another Lys residue (not shown), preferably the amino acid residues at positions 8 - 20 are D- amino acids.
  • Suitable monovalent inhibitors of the present invention are the following:
  • Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys-Lys (SEQ ID NO.: 9) wherein the amino acid residues at positions 1- 13 are preferably D-amino acid residues;
  • Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Lys (SEQ ID NO.: 10) wherein amino acid residues at positions 1 - 11 are preferably D-amino acid residues; Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO.: 11) wherein the amino acid residues are preferably D-amino acid residues;
  • amino acid residues are preferably D-amino acid residues and the serine residue at position 1 has been preferably acety lated;
  • Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO.: 13) wherein the amino acid residues are preferably D-amino acid residues the lysine residue at position 1 is preferably acetylated;
  • Xaa-Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile Val-Val-Cys-Lys-Lys (SEQ ID NO.: 14); wherein Xaa is biotin and the amino acid residues at positions 2 - 14 are preferably D-amino acid residues;
  • Xaa is a lysine residue in which the ⁇ amino group of the lysine forms a peptide bond with a biotin, and amino acid residues at positions 1 - 13 are preferably D-amino acid residues.
  • the inhibitors of the present invention can be synthesized by a suitable method such as by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis.
  • the polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, J. Am. Chem. Soc. 85:2149 (1963). The synthesis is carried out with amino acids that are protected at the alpha-amino terminus. Trifunctional amino acids with labile side- chains are also protected with suitable groups to prevent undesired chemical reactions from occurring during the assembly of the polypeptides.
  • the alpha-amino protecting group is selectively removed to allow subsequent reaction to take place at the amino-terminus. The conditions for the removal of the alpha-amino protecting group do not remove the side-chain protecting groups.
  • alpha-amino protecting groups are those known to be useful in the art of stepwise polypeptide synthesis. Included are acyl type protecting groups (e.g., formyl, trifluoroacetyl, acetyl), aryl type protecting groups (e.g.
  • biotinyl aromatic urethane type protecting groups [e.g., benzyloxycarbonyl (Cbz), substituted benzyloxycarbonyl and 9-fluorenylmethyloxy-carbonyl (Fmoc)], aliphatic urethane protecting groups [e.g., t-butyloxycarbonyl (tBoc), isopropyloxycarbonyl, cyclohexyloxycarbonyl] and alkyl type protecting groups (e.g., benzyl, triphenylmethyl).
  • the preferred protecting groups are tBoc and Fmoc, thus the peptides are said to be synthesized by tBoc and Fmoc chemistry, respectively.
  • the side-chain protecting groups selected must remain intact during coupling and not be removed during the deprotection of the amino-terminus protecting group or during coupling conditions.
  • the side-chain protecting groups must also be removable upon the completion of synthesis, using reaction conditions that will not alter the finished polypeptide.
  • the side-chain protecting groups for trifunctional amino acids are mostly benzyl based.
  • Fmoc chemistry they are mostly tert.-butyl or trityl based.
  • the preferred side-chain protecting groups are tosyl for Arg, cyclohexyl for Asp, 4-methylbenzyl (and acetamidomethyl) for Cys, benzyl for Glu, Ser and Thr, benzyloxymethyl (and dinitrophenyl) for His, 2-Cl-benzyloxycarbonyl for Lys, formyl for Trp and 2-bromobenzyl for Tyr.
  • the preferred side-chain protecting groups are 2,2,5,7,8- pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7- pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg, trityl for Asn, Cys, Gin and His, tert-butyl for Asp, Glu, Ser, Thr and Tyr, tBoc for Lys and Trp.
  • Solid phase synthesis is usually carried out from the carboxyl- terminus by coupling the alpha-amino protected (side-chain protected) amino acid to a suitable solid support.
  • An ester linkage is formed when the attachment is made to a chloromethyl, chlortrityl or hydroxymethyl resin, and the resulting polypeptide will have a free carboxyl group at the C-terminus.
  • an amide resin such as benzhydrylamine or p-methylbenzhydrylamine resin (for tBoc chemistry) and Rink amide or PAL resin (for Fmoc chemistry) is used, an amide bond is formed and the resulting polypeptide will have a carboxamide group at the C-terminus.
  • the C-terminal amino acid is attached to a hydroxylmethyl resin using various activating agents including dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide DIPCDI) and carbonyldiimidazole (CDI). It can be attached to chloromethyl or chlorotrityl resin directly in its cesium tetramethylammonium salt form or in the presence of triethylamine (TEA) or diisopropylethylamine (DIE A).
  • DCC dicyclohexylcarbodiimide
  • DIPCDI N,N'-diisopropylcarbodiimide
  • CDI carbonyldiimidazole
  • the alpha- amino protecting group is removed using various reagents depending on the protecting chemistry (e.g. , tBoc, Fmoc). The extent of Fmoc removal can be monitored at 300-320 nm or by a conductivity cell. After removal of the alpha-amino protecting group, the remaining protected amino acids are coupled stepwise in the required order to obtain the desired sequence.
  • activating agents can be used for the coupling reactions including DCC, DIPCDI, 2-chloro-l,3-dimethylimidium hexafluorophosphate (CIP), benzotriazol-1-yl-oxy-tris- (dimethylamino)-phosphonium hexafluorophosphate (BOP) and its pyrrolidine analog (PyBOP), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP), N- [(lH-benzotriazol-1-yl) - (dimethylamino) methylene] -N-methylmethanaminium hexaflourophosphate N-oxide (HBTU) and its tetrafluoroborate analog (TBTU) or its pyrrolidine analog (HBPyU), (HATU) and its tetrafluoroborate analog (TATU) or pyrrolidine analog (HAPyU).
  • DCC di
  • the most common catalytic additives used in coupling reactions include 4-dimethylaminopyridine (DMAP), 3-hydroxy-3,4-dihydro-4-oxo- 1,2,3-benzotriazine (HODhbt), N-hydroxybenzotriazole (HOBt) and 1- hydroxy-7-azabenzotriazole (HOAt).
  • DMAP 4-dimethylaminopyridine
  • HODhbt 3-hydroxy-3,4-dihydro-4-oxo- 1,2,3-benzotriazine
  • HOBt N-hydroxybenzotriazole
  • 1- hydroxy-7-azabenzotriazole HOAt
  • Amino acid flourides or chlorides may be used for difficult couplings. Each protected amino acid is used in excess (>2.0 equivalents), and the couplings are usually carried out in N-methylpyrrolidone (NMP) or in DMF, CH2O2 or mixtures thereof.
  • NMP N-methylpyrrolidone
  • the extent of completion of the coupling reaction can be monitored at each stage, e.g., by the ninhydrin reaction as described by Kaiser et al, Anal. Biochem. 34:595 (1970). In cases where incomplete coupling is found, the coupling reaction is extended and repeated and may have chaotropic salts added.
  • the coupling reactions can be performed automatically with commercially available instruments such as ABI model 430A, 431A and 433A peptide synthesizers.
  • the peptide- resin is cleaved with a reagent with proper scavengers.
  • the Fmoc peptides are usually cleaved and deprotected by TFA with scavengers (e.g., H2O, ethanedithiol, phenol and thioanisole).
  • the tBoc peptides are usually cleaved and deprotected with liquid HF for 1-2 hours at -5 to 0°C, which cleaves the polypeptide from the resin and removes most of the side-chain protecting groups.
  • Scavengers such as anisole, dimethylsulfide and p-thiocresol are usually used with the liquid HF to prevent cations formed during the cleavage from alkylating and acylating the amino acid residues present in the polypeptide.
  • the formyl group of Trp and dinitrophenyl group of His need to be removed, respectively, by piperidine and thiophenol in DMF prior to the HF cleavage.
  • the acetamidomethyl group of Cys can be removed by mercury(II) acetate and alternatively by iodine, thallium (III) trifluoroacetate or silver tetrafluoroborate which simultaneously oxidize cysteine to cystine.
  • Other strong acids used for tBoc peptide cleavage and deprotection include trifluoromethanesulfonic acid (TFMSA) and trimethylsilyltrifluoroacetate (TMSOTf).
  • peptides of the present invention were assembled from a Fmoc-Amide resin or a Fmoc-L-Lys- (tBoc) - Wang resin on an ABI model 433A synthesizer (Applied Biosystems, Foster City, CA) by solid phase peptide synthesis method as originally described by Merrifield, J. Am.Chem.Soc. 85:2149 (1963) but with Fmoc chemistry.
  • the side chains of trifunctional amino acids were protected by tert.-butyl for Glu, Asp and Ser, trityl for Cys, tert.-butyloxycarbonyl (tBoc) for Lys and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7- pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg.
  • N-a-Fmoc protected amino acids were pre-activated by HATU and 1 -hydroxy- 7- azabenzotriazole (HOAt) prior to coupling to the resin.
  • Dimethylsulfoxide (20%) was added during conditional extended coupling and Fmoc deprotection reactions.
  • the synthesis of the inhibitors SEQ ID NOs: 1, 2, 5, 7, and 9-15 was accomplished by sequential and linear assembly of appropriate D- and L-amino acids and achiral amino acids (Gly and Ahx).
  • the synthesis of the inhibitors SEQ ID NOs: 3, 4, 6, and 8 required orthogonal chain assembly anchored at a Lys residue whose side chain amino group was protected by l-(4,4- dimethyl-2,6-dioxocyclohex-l-ylidene)-ethyl (Dde).
  • SPA scintillation proximity assay
  • SPA technology involves the use of beads coated with scintillant.
  • acceptor molecules such as antibodies, receptors or enzyme substrates which interact with ligands or enzymes in a reversible manner.
  • the substrate peptide is biotinylated at one end and the other end is radiolabelled with low energy emitters such as 125 I or 3 H.
  • the labeled substrate is then incubated with the enzyme.
  • Avidin coated SPA beads are then added which bind to the biotin.
  • the radioactive emitter is no longer in proximity to the scintillant bead and no light emission takes place.
  • Inhibitors of the protease will leave the substrate intact and can be identified by the resulting light emission which takes place in their presence.
  • a suitable assay technique is an HPLC assay in which the resultant reaction mixture containing the NS3 protease, the substrate products and the potential inhibitor is resolved on an HPLC column to determine the extent of the cleavage of the substrate. If the substrate has not been cleaved or the cleavage has been inhibited, then only the intact substrate would be present or a reduced amount of the cleaved product will be shown to be present. If this is the case, then the compound is an effective inhibitor of the NS3 protease.
  • the dosage level of inhibitors necessary for effective therapy to inhibit the HCV NS3 protease will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences. 17th ed.
  • Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index. Merck & Co., Rahway, New Jersey, l ⁇ g per kilogram weight of the patient to 500 mg per kilogram weight of the patient with an appropriate carrier is a range from which the dosage can be chosen. Slow release formulations, or a slow release apparatus will often be utilized for continuous administration.
  • the inhibitors of the HCV NS3 protease of the present invention may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration.
  • Therapeutic formulations may be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
  • Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient.
  • Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics. 8th Ed., Pergamon Press, Parrytown, NY; Remington's Pharmaceutical Sciences. 17th ed. (1990), Mack Publishing Co., Easton, Perm.; Avis, et al. (eds.)(1993) Pharmaceutical Dosage Forms: Parenteral Medications 2d ed., Dekker, NY; Lieberman, et al.
  • compositions Tablets 2d ed., Dekker, NY; and Lieberman, et al. (eds.)(1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY.
  • the therapy of this invention may be combined with or used in association with other chemotherapeutic or chemopreventive agents.
  • bivalent inhibitors of defined by SEQ ID NOs.: 1-10 were synthetically produced as described above and tested for their ability to inhibit the HCV NS3 protease as follows.
  • aqueous solution containing 25 mM TRIS, 50 mM NaCl, .5 mM EDTA, 10% glycerol and .1% NP40 was placed the potential inhibitor, the HCV NS3 protease at a concentration of 0.05 ⁇ M - 0.1 mM, the HCV NS4A cofactor at a concentration of 0.05 ⁇ M - 0.1 ⁇ M and the 5A/5B substrate at a concentration of 50 ⁇ M.
  • This solution was then incubated for approximately 2 hours at 30°C after which the solution was applied to an HPLC to determine if the 5A/5B remained intact and thus the compound was determined to be an inhibitor.
  • Examples of monovalent inhibitors of the HCV NS3 protease are as follows.
  • plasmids were designed and constructed using standard recombinant DNA techniques (Sambrook,Fritsch & Maniatis) to express the HCV protease in E. coli (Fig 2-7). All HCV specific sequences originated from the parental plasmid pBRTM/HCV 1-3011 (Grakoui et ⁇ Z.1993). To express the N-terminal 183 amino acid versions of the protease, a stop codon was inserted into the HCV genome using synthetic oligonucleotides (Fig. 3). The plasmids designed to express the N-terminal 246 amino acid residues were generated by the natural Ncol restriction site at the C-terminus.
  • the plasmid pBRTM/HCV 1-3011 containing the entire HCV genome was digested with the restriction enzymes Sea I and Hpa I and the 7138 bp (base pair) DNA fragment was isolated and cloned to the Sma I site of pSP72 (Promega) to produce the plasmid, pRJ201.
  • the plasmid pRJ 201 was digested with Mse I and the 2106 bp Mse I fragment was isolated and cloned into the Sma I site of the plasmid pBD7.
  • the resulting plasmid pMBM48 was digested with Kas I and Nco I, and the 734 bp DNA fragment after blunt ending with Klenow polymerase was isolated and cloned into Nco I digested, klenow polymerase treated pTrc HIS B seq expression plasmid (Invitrogen). The ligation regenerated a Nco I site at the 5' end and Nsi I site at the 3' end of HCV sequence.
  • the plasmid pTHB HCV NS3 was then digested with Nco I and Nsi I, and treated with klenow polymerase and T4 DNA polymerase, to produce a blunt ended 738 bp DNA fragment which was isolated and cloned into Asp I cut, klenow polymerase treated expression plasmid pQE30 (HIV).
  • the resulting plasmid pBJ 1015 expresses HCV NS3 (246 amino acids) protease.
  • the plasmid pTHB HCV NS3 was digested with Nco I, treated with klenow polymerase, then digested with Bst Y I; and the DNA fragment containing HCV sequence was isolated and cloned into Sma I and Bgl II digested pSP72.
  • the resulting plasmid pTS 49-27 was then digested with Bgl II and Hpa I and ligated with a double stranded oligonucleotide:
  • the plasmid pTS 56-9 was digested with Sph I and Bgl II and the DNA fragment containing HCV sequence was isolated and cloned into a Sph I, Bgl II cut pSP72.
  • the resulting plasmid pJB 1002 digested with Age I and Hpal and ligated to a double stranded oligonucleotide,
  • the plasmid pJB 1006 was digested with NgoM I and Nhe I and the 216 bp DNA fragment was isolated and cloned into Ngo M I, Nhe I cut pBJ 1015 to construct plasmid pBJ 1019.
  • the plasmid pBJ 1019 was digested with Nar I and Pvu II, and treated with Klenow polymerase to fill in 5' ends of Nar I fragments.
  • the expression plasmid pQE31 (Invitrogen) was digested with BamH I, blunt ended with Klenow polymerase.
  • the 717 bp Nar I- Pvu II DNA fragment was isolated and ligated to the 2787 bp BamH I/Klenowed -Mse I (Bal I) fragment of the expression plasmid pQE31 (Invitrogen).
  • the recombinant plasmid, pBJ 1022 obtained after transformation into E.coli expresses His NS3(2-183)-HT which does not contain any HIV protease cleavage site sequence.
  • the plasmid also contains a large deletion in the CAT (Chloramphenicol Acetyl Transferase) gene.
  • the 220 bp DNA fragment was isolated and cloned into the expression plasmid pQE30 which was digested with BamH I and blunt ended with Klenow polymerase prior to ligation.
  • the resulting plasmid pJB 1011 was digested with NgoM I and Hind III and ligated to a double stranded oligonucleotide ,
  • the plasmid pNB 4AHT was digested with Msl I and Xba I.
  • the 1218 bp DNA fragment was isolated and cloned into Age I cut, klenow polymerase treated, Xba I cut vector DNA of pBJ 1019.
  • the ligation results in a substitution of the 183rd amino acid residue valine by a gly cine residue in NS3, and a deletion of amino terminal three amino acid residues of NS4A at the junction.
  • the recombinant plasmid pNB182 ⁇ 4A HT comprising NS3(182aa)-G- NS4A(4-54 amino acid) does not contain NS3/NS4A cleavage site sequence at the junction and is not cleaved by the autocatalytic activity of NS3.
  • the plasmid pNB182 ⁇ 4A HT (SEQ ID NO 8) was digested with Stu I and Nhe I, the 803 bp DNA fragment was isolated and cloned into Stu I and Nhe I cut plasmid pBJ 1022.
  • the resulting plasmid pNB(- V)182- ⁇ 4A HT contains a deletion of the HIV sequence from the amino terminus end of the NS3 sequence and in the CAT gene (SEQ ID NO 23).
  • the recombinant plasmids ⁇ BJ1022 and pNB(-V)182 ⁇ 4A were used to transform separate cultures of E. coli strain M15 [pREP4] (Qiagen), which over-expresses the lac repressor, according to methods recommended by the manufacturer.
  • M15 [pREP4] bacteria harboring recombinant plasmids were grown overnight in broth containing 20g/L bactotrypton, lOg/L bacto-yeast extract, 5g/L NaCl (20-10-5 broth) and supplemented with lOO ⁇ g/ml ampicillin and 25 ⁇ g/ml kanamycin.
  • Cultures were diluted down to O.D.600 of 0.1, then grown at 30°C to O.D.600 of 0.6 to 0.8, after which IPTG was added to a final concentration of lmM. At post-induction 2 to 3 hours, the cells were harvested by pelleting, and the cell pellets were washed with lOOmM Tris, pH 7.5. Cell lysates were prepared as follows: to each ml equivalent of pelleted fermentation broth was added 50 ⁇ l sonication buffer (50mM sodium phosphate, pH 7.8, 0.3M NaCl) with lmg/ml lysozyme; cell suspension was placed on ice for 30 min.
  • 50 ⁇ l sonication buffer 50mM sodium phosphate, pH 7.8, 0.3M NaCl
  • NTA Ni 2+ -Nitrosyl acetic acid
  • the proteins were then purified by placing the extracted lysate on an NTA agarose column.
  • NTA agarose column chromatography was used because the histidine tag which was fused to the N-terminus of the proteases readily binds to the nickel column. This produces a powerful affinity chromatographic technique for rapidly purifying the soluble protease.
  • the column chromatography was performed in a batch mode.
  • the Ni 2+ NTA resin (3ml) was washed twice with 50 ml of Buffer A ( 50mM sodium phosphate pH 7.8 containing 10% glycerol, 0.2% Tween- 20, lOmM BME).
  • the lysate obtained from a 250 ml fermentation (12.5 ml) was incubated with the resin for one hour at 4°C. The flow through was collected by centrifugation. The resin was packed into a 1.0 x 4 cm column and washed with buffer A until the baseline was reached. The bound protein was then eluted with a 20 ml gradient of imidazole (0- 0.5M) in buffer A. Eluted fractions were evaluated by SDS-PAGE and western blot analysis using a rabbit polyclonal antibody to His-HrV 183.
  • the lysate containing the proteins were applied to a POROS metal-chelate affinity column.
  • Perfusion chromatography was performed on a POROS MC metal chelate column (4.6 x 50mm, 1.7 ml) precharged with Ni 2+ .
  • the sample was applied at 10 ml/min and the column was washed with buffer A.
  • the column was step eluted with ten column volumes of buffer A containing 25 mM imidazole.
  • the column was further eluted with a 25 column volume gradient of 25-250 mM imidazole in buffer A. All eluted fractions were evaluated by SDS-PAGE and western blot analysis using rabbit polyclonal antibody.
  • the peptides 5A/5B and 4B/5A substrates (SEQ ID NOs 16, 18, 19, 20 and 21) were synthesized using Fmoc chemistry on an ABI model 431 A peptide synthesizer.
  • the manufacture recommended FastMocTM activation strategy (HBTU/HOBt) was used for the synthesis of 4A activator peptide.
  • a more powerful activator, HATU with or without the additive HO At were employed to assemble 5A/5B substrate peptides on a preloaded Wang resin.
  • the peptides were cleaved off the resin and deprotected by standard TFA cleavage protocol.
  • the peptides were purified on reverse phase HPLC and confirmed by mass spectrometric analysis.
  • the DTEDWCC SMSYTWTGK (SEQ ID NO 16) and soluble HCV NS3 (SEQ ID NO 27) were placed together in an assay buffer.
  • the assay buffer was 50mM sodium phosphate pH 7.8, containing 15% glycerol, lOmM DTT, 0.2% Tween20 and 200 mM NaCl).
  • the protease activity of SEQ ID NO 27 cleaved the substrate into two byproduct peptides, namely 5A and 5B. The substrate and two byproduct peptides were separated on a reversed- phase HPLC column.
  • Xaa is lysine having a peptide bond between its ⁇ -amino group and the carboxyl group of lysine at position 8.
  • the carboxyl group of the Xaa forms a peptide bond with the ⁇ -amino group of another lysine (not shown);
  • the lysine residue at position 8 has a peptide bond between the carboxyl group of Acp and the a amino group of the lysine, and the ⁇ amino group of the lysine at position 8 forms a peptide bond with the carboxyl group of the cysteine residue at position 9 and the amino acid residues at positions 9-21 are preferably D-amino acid residues;
  • Xaa is a lysine wherein the ⁇ amino group of which forms a peptide bond with the carboxyl group of the cysteine residue at position 8 and the carboxyl group of the lysine residue forms a peptide bond with an ⁇ amino group of another lysine residue (not shown), preferably the amino acid residues at positions 8 - 20 are D- amino acid residues.
  • amino acid residues at positions 1- 13 are preferably D-amino acid residues and lysine at position 14 is preferably an L-amino acid residue;
  • amino acid residues are preferably D-amino acid residues.
  • amino acid residues are preferably D-amino acids and the serine residue at position 1 is preferably acetylated;
  • Xaa is biotin and the amino acid residues at positions 2 - 14 are preferably D-amino acids;
  • Xaa is a lysine residue in which the ⁇ amino group of the lysine forms a peptide bond with a biotin and amino acid residues at positions 1 - 13 are preferably D-amino acid residues.
  • NAME/KEY NS4A AGC ACC TGG GTG CTC GTT GGC GGC GTC CTG GCT GCT CTG GCC GCG 45 Ser Thr Trp Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala 1 5 10 15
  • NAME/KEY NS4A/4B Cleavage Site Tyr Gin Glu Phe Asp Glu Met Glu Glu Cys Ser Gin His Leu Pro
  • Trp He Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inhibitor is a bivalent inhibitor comprised of a subsequence, a mutated subsequence or a mutated full-length of a substrate of the NS3 protease linked to a subsequence, a mutated subsequence or a mutated full-length subsequence of the HCV NS4A cofactor.

Description

SYNTHETIC INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE
BACKGROUND OF THE INVENTION
Hepatitis C virus (HCV) is considered to be the major etiological agent of non-A non-B (NANB) hepatitis, chronic liver disease, and hepatocellular carcinoma (HCC) around the world. The viral infection accounts for greater than 90% of transfusion -associated hepatitis in U.S. and it is the predominant form of hepatitis in adults over 40 years of age. Almost all of the infections result in chronic hepatitis and nearly 20% develop liver cirrhosis.
The virus particle has not been identified due to the lack of an efficient in vitro replication system and the extremely low amount of HCV particles in infected liver tissues or blood. However, molecular cloning of the viral genome has been accomplished by isolating the messenger RNA (mRNA) from the serum of infected chimpanzees then cloned using recombinant methodologies. [Grakoui A. et al. }. Virol. 67: 1385 - 1395 (1993)] It is now known that HCV contains a positive strand RNA genome comprising approximately 9400 nucleotides, whose organization is similar to that of f la vi viruses and pestiviruses. The genome of HCV, like that of flavi- and pestiviruses, encodes a single large polyprotein of about 3000 amino acids which undergoes proteolysis to form mature viral proteins in infected cells.
Cell-free translation of the viral polyprotein and cell culture expression studies have established that the HCV polyprotein is processed by cellular and viral proteases to produce the putative structural and nonstructural (NS) proteins. At least nine mature viral proteins are produced from the polyprotein by specific proteolysis. The order and nomenclature of the cleavage products are as follows: NH2-C-El-E2-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH. The three amino terminal putative structural proteins, C (capsid), El, and E2 ( two envelope glycoproteins), are believed to be cleaved by host signal peptidases of the endoplasmic reticulum(ER) . The host enzyme is also responsible for generating the amino terminus of NS2 . The proteolytic processing of the nonstructural proteins are carried out by the viral proteases: NS2-3 and NS3, contained within the viral polyprotein. The NS2-3 protease catalyzes the cleavage between NS2 and NS3. It is a metalloprotease and requires both NS2 and the protease domain of NS3. The NS3 protease catalyzes the rest of the cleavages of the substrates in the nonstructural part of the polyprotein. The NS3 protein contains 631 amino acid residues and is comprised of two enzymatic domains: the protease domain contained within amino acid residues 1-181 and a helicase ATPase domain contained within the rest of the protein. It is not known if the 70 kD NS3 protein is cleaved further in infected cells to separate the protease domain from the helicase domain, however, no cleavage has been observed in cell culture expression studies.
The NS3 protease is a member of the serine proteinase class of enzymes. It contains His, Asp, and Ser as the catalytic triad. Mutation of the catalytic triad residues abolishes the cleavages at substrates NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B. The cleavage between NS3 and NS4A is mediated through an intramolecular enzymatic reaction, whereas the cleavages at NS4A/4B, 4B/5A, 5A/5B sites occur in a trans enzymatic reaction.
Experiments using transient expression of various forms of HCV
NS polyproteins in mammalian cells have established that the NS3 serine protease is necessary but not sufficient for efficient processing of all these cleavages. Like flaviviruses, the HCV NS3 protease also requires a cofactor to catalyze some of these cleavage reactions. In addition to the serine protease NS3, the NS4A protein is absolutely required for the cleavage of the substrate at the NS3/4A and 4B/5A sites and increases the efficiency of cleavage of the substrate between 5A/5B, and possibly 4A/4B.
Because the HCV NS3 protease cleaves the non-structural HCV proteins which are necessary for the HCV replication, the NS3 protease can be a target for the development of therapeutic agents against the HCV virus. Thus there is a need for the development of inhibitors of the HCV protease.
SUMMARY OF THE INVENTION
The present invention fills this need by providing for a bivalent inhibitor of an hepatitis C NS3 protease comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide.
The present application further provides for an inhibitor of an HCV protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence, or a mutated full-length sequence of a substrate of the HCV NS3 protease.
The present application further provides for an inhibitor of an HCV NS3 protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of an HCV NS4A polypeptide.
The present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full- length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide.
The present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease. The present invention further comprises a method for treating an individual infected with the HCV virus comprising administering an inhibitor of an HCV NS3 protease to said individual, said inhibitor being comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of an HCV NS4A polypeptide.
The present invention further comprises a pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being an inhibitor of an HCV NS3 protease, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide, and a pharmaceutical carrier.
The present invention further provides for a pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, said inhibitor being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.
The present invention further provides for a pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, wherein said inhibitor is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length subsequence of an HCV NS4A polypeptide. BRIEF DESCRIPTION OF THE FIGURES
Figure 1 schematically depicts an embodiment of a bivalent inhibitor of the present invention.
Figure 2 depicts the recombinant synthesis of plasmid pBJ1015.
Figure 3 depicts the recombinant synthesis of plasmid pTS56-9.
Figure 4 depicts the recombinant synthesis of plasmid pJB1006.
Figure 5 depicts the recombinant synthesis of plasmid pBJ1022.
Figure 6 depicts the recombinant synthesis of plasmid pNB(-V)182Δ4AHT.
Figure 7 depicts the recombinant synthesis of plasmid pT5His/HIV/183.
DETAILED DESCRIPTION OF THE INVENTION
The teachings of all references cited are incorporated herein in their entirety by reference.
The present invention are inhibitors of the HCV NS3 protease. The present invention relates to inhibitors of the HCV NS3 protease which inhibit either the interaction of a substrate or cofactor NS4A with the NS3 protease or a bivalent inhibitor which inhibits the interaction of the NS3 protease with both cofactor NS4A and a substrate of the NS3 protease. Compared to inhibitors targeting only at a single binding site, bivalent enzyme inhibitors may provide additional advantages in terms of higher binding affinity (potency), as well as enhanced specificity against similar cellular host enzymes for reduced toxicity effects.
Design Strategy of Bivalent Inhibitors of HCV NS3 Protease
The basic strategy for the design of bivalent inhibitors of HCV NS3 protease involved the devise of a molecular framework consisting of three individual components: 1. a region appropriate for binding to a substrate binding site;
2. a region suitable for binding to the NS4A binding site;
3. a flexible linker region connecting regions (1) and (2) which would allow the two end regions to bind to their respective binding sites.
Schematically, this is represented by Figure 1 in which the substrate subsequence is depicted as block, 10, being attached to linker 12, and said linker 12 being attached to the polypeptide NS4A designated 14.
Since the NS3 protease cleaves the HCV polyprotein at the NS3/4A, 4A/4B, 4B/5A and 5A/5B junctions, then subsequences of or mutated subsequences of these sites can be used as substrate inhibitors. A substrate inhibitor which is a subsequence of the inhibitor should be a subsequence which is prior to or after the cleavage site but preferably should not contain the cleavage site. A mutated subsequence or mutated full-length sequence of the substrate can be used if the cleavage site is mutated so that the cleavage of the substrate does not occur cleavage leads to mechanism-based inactivation of the protease.
For example, the NS3/4A cleavage site contains the following sequence:
Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu 5 10 15
Val Gly Gly Val Leu (SEQ. ID NO.: 26)
20
The cleavage site is between the threonine at position 10 and the serine at position 11. Any subsequence inhibitor should preferably be before the serine or after the threonine residue. Alternatively, a mutated subsequence or sequence can be produced by changing the threonine /serine cleavage site at position 10-11 to eliminate the cleavage site. NS4A/4B contains the following sequence.
Tyr Gin Glu Phe Asp Glu Met Glu Glu Cys Ser Gin His Leu Pro 5 10 15 Tyr He Glu Gin Gly (SEQ ID NO.: 27).
20
The cleavage site is between the cysteine residue at position 10 and the serine at position 11. Any subsequence should preferably be before the serine or after the cysteine, but should preferably not contain both the cysteine and the serine. Alternatively, a mutated subsequence or sequence can be produced by changing the cysteine /serine cleavage site at position 10 - 11 to eliminate the cleavage site.
NS4B/5A contains the following sequence.
Trp He Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu 5 10 15
Arg Asp lie Trp Asp (SEQ ID NO.: 28) 20
The cleavage site is between the cysteine at position 10 and serine at position 11. Any subsequence should preferably end before the serine or start after the cysteine but should preferably not contain both the serine and the cysteine. Alternatively, a mutated subsequence or sequence can be produced by changing the cysteine /serine cleavage sit at position 10 - 11 to eliminate the cleavage site.
NS5A/5B contains the following sequence. Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr
5 10 15
Gly (SEQ.IDNO.:25)
The cleavage site is between the cysteine at position 8 and the serine at position 9. Any subsequence should preferably end at the cysteine or start at the serine, but should preferably not contain both the cysteine and the serine. Alternatively, a mutated sequence or subsequence can be produced by changing the cysteine /serine cleavage site at position 8 - 9 to eliminate the cleavage site.
Linker 12 can be any chemical entity that can form a bond with polypeptides 10 and 14. Preferably the linker should be equivalent in length to a carbon chain having about 7-14 carbon residues. Examples of suitable linkers are two 6-aminocaproic acid (Acp) residues or an Acp and Lys wherein one of the polypeptides 10 or 14 form a peptide bond with the ε amine of lysine.
Examples of bivalent inhibitors of the present invention are the following:
Glu-Asp-Val-Val-Cys-Cys-Acp-Acp-Cys-Val-Val-Ile-Val-
Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO: 1)
Glu-Asp-Val-Val-Cys-Cys-Acp-Cys-Val-Val-Ile-Val - Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys-Lys (SEQ ID NO:2)
Glu-Asp-Val-Val-Cys-Cys-Acp-Xaa-Lys-Gly-Ser-Leu-Val- Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO: 3)
wherein Xaa is a lysine residue having a peptide bond between its ε-amino and the carboxyl group of the following lysine which forms a peptide bond with the glycine at position 10. Furthermore, the glutamic acid residue at position 1 may or may not be acety lated.
Glu-Asp-Val-Val-Cys-Cys-Xaa-Lys-Gly-Ser-Leu-Val - Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO: 4)
wherein Xaa is Lysine having a peptide bond between its ε-amino and the carboxyl group of the following lysine which forms a peptide bond with the Gly; furthermore, the carboxyl group of the Xaa forms a peptide bond with the α-amino group of another lysine (not shown);
Glu-Asp-Val-Val-Cys-Cys-Acp-Acp-Lys-Gly-Ser-Leu-Val- Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO: 5) wherein the amino acids at positions 9-21 are preferably D-amino acids;
Glu-Asp-Val-Val-Cys-Cys-Acp-Lys-Cys-Val-Val-Ile-
Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO: 6)
wherein the lysine residue at position 8 has a peptide bond between the carboxyl of Acp and the α amino group of the lysine, and the ε amino group of the lysine at position 8 forms a peptide bond with the carboxyl group of the cysteine residue at position 9 and the amino acid residues at positions 9-21 are preferably D-amino acid residues;
Glu-Asp-Val-Val-Cys-Cys-Acp-Lys-Gly-Ser-Leu-Val-Ile-Arg- Gly-Val-Ile-Val-Val-Cys-Lys (SEQ ID NO: 7)
wherein amino acid residues at positions 8-20 are preferably D- amino acid residues;
Glu- Asp-Val -Val -Cys -Cys -Xaa-Cys -Val -Val - I le- Val -Gly-
Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO: 8)
wherein Xaa is a Lys which forms a peptide bond between its ε- amino acid and the carboxyl group of the Cys residue at position 8 and the carboxyl group of the Lys residue forms a peptide bond with an alpha amino group of another Lys residue (not shown), preferably the amino acid residues at positions 8 - 20 are D- amino acids.
Examples of suitable monovalent inhibitors of the present invention are the following:
Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys-Lys (SEQ ID NO.: 9) wherein the amino acid residues at positions 1- 13 are preferably D-amino acid residues;
Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Lys (SEQ ID NO.: 10) wherein amino acid residues at positions 1 - 11 are preferably D-amino acid residues; Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO.: 11) wherein the amino acid residues are preferably D-amino acid residues;
Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val (SEQ ID NO.: 12)
wherein the amino acid residues are preferably D-amino acid residues and the serine residue at position 1 has been preferably acety lated;
Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys (SEQ ID NO.: 13) wherein the amino acid residues are preferably D-amino acid residues the lysine residue at position 1 is preferably acetylated;
Xaa-Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile Val-Val-Cys-Lys-Lys (SEQ ID NO.: 14); wherein Xaa is biotin and the amino acid residues at positions 2 - 14 are preferably D-amino acid residues;
Lys-Gly-Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val-Val-Cys-Xaa-Lys (SEQ ID NO.: 15);
Xaa is a lysine residue in which the ε amino group of the lysine forms a peptide bond with a biotin, and amino acid residues at positions 1 - 13 are preferably D-amino acid residues.
The inhibitors of the present invention can be synthesized by a suitable method such as by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, J. Am. Chem. Soc. 85:2149 (1963). The synthesis is carried out with amino acids that are protected at the alpha-amino terminus. Trifunctional amino acids with labile side- chains are also protected with suitable groups to prevent undesired chemical reactions from occurring during the assembly of the polypeptides. The alpha-amino protecting group is selectively removed to allow subsequent reaction to take place at the amino-terminus. The conditions for the removal of the alpha-amino protecting group do not remove the side-chain protecting groups.
The alpha-amino protecting groups are those known to be useful in the art of stepwise polypeptide synthesis. Included are acyl type protecting groups (e.g., formyl, trifluoroacetyl, acetyl), aryl type protecting groups (e.g. , biotinyl), aromatic urethane type protecting groups [e.g., benzyloxycarbonyl (Cbz), substituted benzyloxycarbonyl and 9-fluorenylmethyloxy-carbonyl (Fmoc)], aliphatic urethane protecting groups [e.g., t-butyloxycarbonyl (tBoc), isopropyloxycarbonyl, cyclohexyloxycarbonyl] and alkyl type protecting groups (e.g., benzyl, triphenylmethyl). The preferred protecting groups are tBoc and Fmoc, thus the peptides are said to be synthesized by tBoc and Fmoc chemistry, respectively.
The side-chain protecting groups selected must remain intact during coupling and not be removed during the deprotection of the amino-terminus protecting group or during coupling conditions. The side-chain protecting groups must also be removable upon the completion of synthesis, using reaction conditions that will not alter the finished polypeptide. In tBoc chemistry, the side-chain protecting groups for trifunctional amino acids are mostly benzyl based. In Fmoc chemistry, they are mostly tert.-butyl or trityl based.
In tBoc chemistry, the preferred side-chain protecting groups are tosyl for Arg, cyclohexyl for Asp, 4-methylbenzyl (and acetamidomethyl) for Cys, benzyl for Glu, Ser and Thr, benzyloxymethyl (and dinitrophenyl) for His, 2-Cl-benzyloxycarbonyl for Lys, formyl for Trp and 2-bromobenzyl for Tyr. In Fmoc chemistry, the preferred side-chain protecting groups are 2,2,5,7,8- pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7- pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg, trityl for Asn, Cys, Gin and His, tert-butyl for Asp, Glu, Ser, Thr and Tyr, tBoc for Lys and Trp.
Solid phase synthesis is usually carried out from the carboxyl- terminus by coupling the alpha-amino protected (side-chain protected) amino acid to a suitable solid support. An ester linkage is formed when the attachment is made to a chloromethyl, chlortrityl or hydroxymethyl resin, and the resulting polypeptide will have a free carboxyl group at the C-terminus. Alternatively, when an amide resin such as benzhydrylamine or p-methylbenzhydrylamine resin (for tBoc chemistry) and Rink amide or PAL resin (for Fmoc chemistry) is used, an amide bond is formed and the resulting polypeptide will have a carboxamide group at the C-terminus. These resins, whether polystyrene- or polyamide-based or polyethyleneglycol-grafted, with or without a handle or linker, with or without the first amino acid attached, are commercially available, and their preparations have been described by Stewart et al (1984)., "Solid Phase Peptide Synthesis" (2nd Edition), Pierce Chemical Co., Rockford, IL.; and Bayer & Rapp (1986) Chem. Pept. Prot. 3, 3; and Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford.
The C-terminal amino acid, protected at the side-chain if necessary and at the alpha-amino group, is attached to a hydroxylmethyl resin using various activating agents including dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide DIPCDI) and carbonyldiimidazole (CDI). It can be attached to chloromethyl or chlorotrityl resin directly in its cesium tetramethylammonium salt form or in the presence of triethylamine (TEA) or diisopropylethylamine (DIE A). First amino acid attachment to an amide resin is the same as amide bond formation during coupling reactions
Following the attachment to the resin support, the alpha- amino protecting group is removed using various reagents depending on the protecting chemistry (e.g. , tBoc, Fmoc). The extent of Fmoc removal can be monitored at 300-320 nm or by a conductivity cell. After removal of the alpha-amino protecting group, the remaining protected amino acids are coupled stepwise in the required order to obtain the desired sequence.
Various activating agents can be used for the coupling reactions including DCC, DIPCDI, 2-chloro-l,3-dimethylimidium hexafluorophosphate (CIP), benzotriazol-1-yl-oxy-tris- (dimethylamino)-phosphonium hexafluorophosphate (BOP) and its pyrrolidine analog (PyBOP), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP), N- [(lH-benzotriazol-1-yl) - (dimethylamino) methylene] -N-methylmethanaminium hexaflourophosphate N-oxide (HBTU) and its tetrafluoroborate analog (TBTU) or its pyrrolidine analog (HBPyU), (HATU) and its tetrafluoroborate analog (TATU) or pyrrolidine analog (HAPyU). The most common catalytic additives used in coupling reactions include 4-dimethylaminopyridine (DMAP), 3-hydroxy-3,4-dihydro-4-oxo- 1,2,3-benzotriazine (HODhbt), N-hydroxybenzotriazole (HOBt) and 1- hydroxy-7-azabenzotriazole (HOAt). Amino acid flourides or chlorides may be used for difficult couplings. Each protected amino acid is used in excess (>2.0 equivalents), and the couplings are usually carried out in N-methylpyrrolidone (NMP) or in DMF, CH2O2 or mixtures thereof. The extent of completion of the coupling reaction can be monitored at each stage, e.g., by the ninhydrin reaction as described by Kaiser et al, Anal. Biochem. 34:595 (1970). In cases where incomplete coupling is found, the coupling reaction is extended and repeated and may have chaotropic salts added. The coupling reactions can be performed automatically with commercially available instruments such as ABI model 430A, 431A and 433A peptide synthesizers.
After the entire assembly of the desired peptide, the peptide- resin is cleaved with a reagent with proper scavengers. The Fmoc peptides are usually cleaved and deprotected by TFA with scavengers (e.g., H2O, ethanedithiol, phenol and thioanisole). The tBoc peptides are usually cleaved and deprotected with liquid HF for 1-2 hours at -5 to 0°C, which cleaves the polypeptide from the resin and removes most of the side-chain protecting groups. Scavengers such as anisole, dimethylsulfide and p-thiocresol are usually used with the liquid HF to prevent cations formed during the cleavage from alkylating and acylating the amino acid residues present in the polypeptide. The formyl group of Trp and dinitrophenyl group of His need to be removed, respectively, by piperidine and thiophenol in DMF prior to the HF cleavage. The acetamidomethyl group of Cys can be removed by mercury(II) acetate and alternatively by iodine, thallium (III) trifluoroacetate or silver tetrafluoroborate which simultaneously oxidize cysteine to cystine. Other strong acids used for tBoc peptide cleavage and deprotection include trifluoromethanesulfonic acid (TFMSA) and trimethylsilyltrifluoroacetate (TMSOTf).
In particular the peptides of the present invention were assembled from a Fmoc-Amide resin or a Fmoc-L-Lys- (tBoc) - Wang resin on an ABI model 433A synthesizer (Applied Biosystems, Foster City, CA) by solid phase peptide synthesis method as originally described by Merrifield, J. Am.Chem.Soc. 85:2149 (1963) but with Fmoc chemistry. The side chains of trifunctional amino acids were protected by tert.-butyl for Glu, Asp and Ser, trityl for Cys, tert.-butyloxycarbonyl (tBoc) for Lys and 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7- pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg. N-a-Fmoc protected amino acids were pre-activated by HATU and 1 -hydroxy- 7- azabenzotriazole (HOAt) prior to coupling to the resin. Dimethylsulfoxide (20%) was added during conditional extended coupling and Fmoc deprotection reactions. The synthesis of the inhibitors SEQ ID NOs: 1, 2, 5, 7, and 9-15 was accomplished by sequential and linear assembly of appropriate D- and L-amino acids and achiral amino acids (Gly and Ahx). The synthesis of the inhibitors SEQ ID NOs: 3, 4, 6, and 8 required orthogonal chain assembly anchored at a Lys residue whose side chain amino group was protected by l-(4,4- dimethyl-2,6-dioxocyclohex-l-ylidene)-ethyl (Dde). For example, for the preparation of the inhibitor SEQ ID NO: 3, Ac-Glu-Asp-Val-Val-Cys-Cys- Acp-Lys-(Amide resin) (SEQ ID NO: 29) was first assembled. Then the Dde protecting group on the Lys residue was removed by 2% hydrazine in dimethylformamide (Bycroft, B.W. et al J. Chem. Soc. Chem. Commun. 1993, 778). Finally the second arm
Cys-Val-Val-Ile-Val-Gly-Arg-Ile-Val-Leu-Ser-Gly-Lys (SEQ ID NO:30) was sequentially assembled from the side chain amino group. The assembled peptide was cleaved from the resin with simultaneous deprotection of side chain protecting groups for three hours by trifluoroacetic acid (TFA) with proper scavengers (80% TFA : 4% phenol : 4% H2O, 4% thioanisole : 4% ethanedithiol : 4% triisopropylsilane). The cleaved peptide was separated from the resin by filtration and precipitated and repeatedly washed in anhydrous ethyl ether. The precipitated peptide was lyophilized in H2O overnight. The lyophilized crude peptide was purified by reverse phase HPLC. The purified peptide was further analyzed by HPLC, mass spectroscopy and amino acid analysis.
One can ascertain if a potential compound is effective as an inhibitor of the HCV NS3 protease by using a high throughput assay utilizing the NS3 protease, the NS4 cofactor and the peptide substrates, either 4B/5A or 5A/5B. These can be used to screen for compounds which inhibit proteolytic activity of the protease. One does this by developing techniques for determining whether or not a compound will inhibit the NS3 protease from cleaving the viral substrates. If the substrates are not cleaved, the virus cannot replicate. One example of such a high throughput assay is the scintillation proximity assay (SPA). SPA technology involves the use of beads coated with scintillant.
Bound to the beads are acceptor molecules such as antibodies, receptors or enzyme substrates which interact with ligands or enzymes in a reversible manner.
For a typical SPA based protease assay the substrate peptide is biotinylated at one end and the other end is radiolabelled with low energy emitters such as 125I or 3H. The labeled substrate is then incubated with the enzyme. Avidin coated SPA beads are then added which bind to the biotin. When the substrate peptide is cleaved by the protease, the radioactive emitter is no longer in proximity to the scintillant bead and no light emission takes place. Inhibitors of the protease will leave the substrate intact and can be identified by the resulting light emission which takes place in their presence.
Another example of a suitable assay technique is an HPLC assay in which the resultant reaction mixture containing the NS3 protease, the substrate products and the potential inhibitor is resolved on an HPLC column to determine the extent of the cleavage of the substrate. If the substrate has not been cleaved or the cleavage has been inhibited, then only the intact substrate would be present or a reduced amount of the cleaved product will be shown to be present. If this is the case, then the compound is an effective inhibitor of the NS3 protease.
Pharmaceutical Compositions
The dosage level of inhibitors necessary for effective therapy to inhibit the HCV NS3 protease will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences. 17th ed. (1990), Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. See also Langer (1990) Science 249:1527-1533. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index. Merck & Co., Rahway, New Jersey, lμg per kilogram weight of the patient to 500 mg per kilogram weight of the patient with an appropriate carrier is a range from which the dosage can be chosen. Slow release formulations, or a slow release apparatus will often be utilized for continuous administration.
The inhibitors of the HCV NS3 protease of the present invention may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds.) (1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics. 8th Ed., Pergamon Press, Parrytown, NY; Remington's Pharmaceutical Sciences. 17th ed. (1990), Mack Publishing Co., Easton, Perm.; Avis, et al. (eds.)(1993) Pharmaceutical Dosage Forms: Parenteral Medications 2d ed., Dekker, NY; Lieberman, et al. (eds.)(1990) Pharmaceutical Dosage Forms: Tablets 2d ed., Dekker, NY; and Lieberman, et al. (eds.)(1990) Pharmaceutical Dosage Forms: Disperse Systems Dekker, NY. The therapy of this invention may be combined with or used in association with other chemotherapeutic or chemopreventive agents.
The following examples are included to illustrate but not to limit the present invention.
Example 1
Bivalent Inhibitors of HCV NS3 Protease
The bivalent inhibitors of defined by SEQ ID NOs.: 1-10 were synthetically produced as described above and tested for their ability to inhibit the HCV NS3 protease as follows.
Into an aqueous solution containing 25 mM TRIS, 50 mM NaCl, .5 mM EDTA, 10% glycerol and .1% NP40 was placed the potential inhibitor, the HCV NS3 protease at a concentration of 0.05 μM - 0.1 mM, the HCV NS4A cofactor at a concentration of 0.05 μM - 0.1 μM and the 5A/5B substrate at a concentration of 50 μM. This solution was then incubated for approximately 2 hours at 30°C after which the solution was applied to an HPLC to determine if the 5A/5B remained intact and thus the compound was determined to be an inhibitor. However, if the HPLC showed that 5 A and 5B were present without the 5A/5B then the compound is not an inhibitor. The potential inhibitors were assayed at several different concentrations to determine the concentration which produced 50% inhibition of the HCV NS3 protease. The results are shown below.
Inhibitor ICso fμM)
SEQ ID NO:l 0.6
50571-120
SEQ ID NO:2 3.0
50962-13
SEQ ID NO:3 3.0
50828-001
SEQ ID NO:4 3 - 30
50962-22
SEQ ID NO:5 0.2
50571-144
SEQ ID NO:6 2.0
50571-150
SEQ ID NO:7 0.2
50828-131
SEQ ID NO:8 0.2
50962-24
Example 2
Monovalent Inhibitors of the HCV NS3 Protease
Examples of monovalent inhibitors of the HCV NS3 protease are as follows.
Inhibitor ICsoiμM)
SEQ ID NO.: 9 0.2
50828-129
SEQ ID NO.: 10 5
50962-004
SEQ ID NO.: 11 0.2
50828-70
SEQ ID NO.: 12 0.6
50828-116
SEQ ID NO.: 13 2.0
50571-147
SEQ ID NO.: 14 0.4
50962-047
SEQ ID NO.: 15 0.4
50962-050
Examples 3
Production of HCV NS3 Protease
Plasmid constructions.
Several plasmids were designed and constructed using standard recombinant DNA techniques (Sambrook,Fritsch & Maniatis) to express the HCV protease in E. coli (Fig 2-7). All HCV specific sequences originated from the parental plasmid pBRTM/HCV 1-3011 (Grakoui et αZ.1993). To express the N-terminal 183 amino acid versions of the protease, a stop codon was inserted into the HCV genome using synthetic oligonucleotides (Fig. 3). The plasmids designed to express the N-terminal 246 amino acid residues were generated by the natural Ncol restriction site at the C-terminus.
i) Construction of the plasmid pBJ1015 (Figure 2)
The plasmid pBRTM/HCV 1-3011 containing the entire HCV genome (Grakoui A., et al, J. Virol. 67: 1385-1395) was digested with the restriction enzymes Sea I and Hpa I and the 7138 bp (base pair) DNA fragment was isolated and cloned to the Sma I site of pSP72 (Promega) to produce the plasmid, pRJ201. The plasmid pRJ 201 was digested with Mse I and the 2106 bp Mse I fragment was isolated and cloned into the Sma I site of the plasmid pBD7. The resulting plasmid pMBM48 was digested with Kas I and Nco I, and the 734 bp DNA fragment after blunt ending with Klenow polymerase was isolated and cloned into Nco I digested, klenow polymerase treated pTrc HIS B seq expression plasmid (Invitrogen). The ligation regenerated a Nco I site at the 5' end and Nsi I site at the 3' end of HCV sequence. The plasmid pTHB HCV NS3 was then digested with Nco I and Nsi I, and treated with klenow polymerase and T4 DNA polymerase, to produce a blunt ended 738 bp DNA fragment which was isolated and cloned into Asp I cut, klenow polymerase treated expression plasmid pQE30 (HIV). The resulting plasmid pBJ 1015 expresses HCV NS3 (246 amino acids) protease.
(ii) Construction of the plasmid pTS 56-9 with a stop codon after amino acid 183 (Figure 3)
The plasmid pTHB HCV NS3 was digested with Nco I, treated with klenow polymerase, then digested with Bst Y I; and the DNA fragment containing HCV sequence was isolated and cloned into Sma I and Bgl II digested pSP72. The resulting plasmid pTS 49-27 was then digested with Bgl II and Hpa I and ligated with a double stranded oligonucleotide:
GA TCA CCG GTC TAG ATCT
T GGC CAG ATC TAGA (SEQ ID NO 18) to produce pTS 56-9. Thus, a stop codon was placed directly at the end of DNA encoding the protease catalytic domain of the NS3 protein. This enabled the HCV protease to be expressed independently from the helicase domain of the NS3 protein.
(iii) Construction of the plasmid pJB 1006 Fused with a peptide of positively charged amino acids at the carboxy terminus of NS3 183 (Figure 4).
The plasmid pTS 56-9 was digested with Sph I and Bgl II and the DNA fragment containing HCV sequence was isolated and cloned into a Sph I, Bgl II cut pSP72. The resulting plasmid pJB 1002 digested with Age I and Hpal and ligated to a double stranded oligonucleotide,
CCG GTC CGG AAG AAA AAG AGA CGC TAG C AG GCC TTC TTT TTC TCT GCG ATC G (SEQ ID NO 19), to construct pJB 1006. This fused the hydrophilic, solubilizing motif onto the NS3 protease.
(iv) Construction of the plasmid pBJ 1022 expressing His-NS3(183)-HT in E.coli (Figure 5)
The plasmid pJB 1006 was digested with NgoM I and Nhe I and the 216 bp DNA fragment was isolated and cloned into Ngo M I, Nhe I cut pBJ 1015 to construct plasmid pBJ 1019. The plasmid pBJ 1019 was digested with Nar I and Pvu II, and treated with Klenow polymerase to fill in 5' ends of Nar I fragments. The expression plasmid pQE31 (Invitrogen) was digested with BamH I, blunt ended with Klenow polymerase. The 717 bp Nar I- Pvu II DNA fragment was isolated and ligated to the 2787 bp BamH I/Klenowed -Mse I (Bal I) fragment of the expression plasmid pQE31 (Invitrogen). The recombinant plasmid, pBJ 1022, obtained after transformation into E.coli expresses His NS3(2-183)-HT which does not contain any HIV protease cleavage site sequence. The plasmid also contains a large deletion in the CAT (Chloramphenicol Acetyl Transferase) gene.
(v) Construction of the plasmid pNB(-V)182-Δ4A HT (Figure 6) The plasmid pMBM 48 was digested with Eag I and Xho I, treated with Klenow polymerase and the 320 bp DNA fragment was isolated and cloned into BamH I cut , blunt ended pSP 72 to construct the plasmid pJB1004. The 320 bp fragment encodes 7 amino acid from carboxy terminal of NS3(631), all of NS4A, and the amino terminal 46 amino acid of NS4B. The recombinant plasmid pJB1004 was digested with Eag I and Cel 2, blunt ended with Klenow polymerase. The 220 bp DNA fragment was isolated and cloned into the expression plasmid pQE30 which was digested with BamH I and blunt ended with Klenow polymerase prior to ligation. The resulting plasmid pJB 1011 was digested with NgoM I and Hind III and ligated to a double stranded oligonucleotide ,
CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC CAG GAA TTC GT TAA TAT GGA CTG TCC CTC CAA GAG ATG GTC CTT AAG
GAT GAG ATG GAA GAG TGC CGG AAG AAA AAG AGA CGC A
CTA CTC TAC CTT CTC ACG GCC TTC TTT TTC TCT GCG TTC GA
(SEQ ID NO 20)
to construct the plasmid pNB 4A HT. The plasmid pNB 4AHT was digested with Msl I and Xba I. The 1218 bp DNA fragment was isolated and cloned into Age I cut, klenow polymerase treated, Xba I cut vector DNA of pBJ 1019. The ligation results in a substitution of the 183rd amino acid residue valine by a gly cine residue in NS3, and a deletion of amino terminal three amino acid residues of NS4A at the junction. The recombinant plasmid pNB182Δ4A HT comprising NS3(182aa)-G- NS4A(4-54 amino acid) does not contain NS3/NS4A cleavage site sequence at the junction and is not cleaved by the autocatalytic activity of NS3. Finally the plasmid pNB182Δ4A HT (SEQ ID NO 8) was digested with Stu I and Nhe I, the 803 bp DNA fragment was isolated and cloned into Stu I and Nhe I cut plasmid pBJ 1022. The resulting plasmid pNB(- V)182-Δ4A HT contains a deletion of the HIV sequence from the amino terminus end of the NS3 sequence and in the CAT gene (SEQ ID NO 23).
(vi) Construction of the plasmid pT5 His HIV-NS3 (Figure 7) The plasmid pTS56-9 was digested with Bgl II, and treated with Klenow polymerase to fill in 5' ends. The plasmid was then digested with NgoM I and the blunt ended Bgl II/NgoMI fragment containing the NS3 sequence was isolated and ligated to the Sgll, Klenow treated NgmMI cut and Sal I klenowed pBJ 1015. The resulting plasmid is designated pT5His HTv* 183.
Example 4
Purification of HCV NS3 Protease having a Solubilizing Motif
Purification of Hisl82HT (SEQ ID NO 4) and His (-V1182Δ4AHT (SEQ ID NO 8)
The recombinant plasmids ρBJ1022 and pNB(-V)182Δ4A were used to transform separate cultures of E. coli strain M15 [pREP4] (Qiagen), which over-expresses the lac repressor, according to methods recommended by the manufacturer. M15 [pREP4] bacteria harboring recombinant plasmids were grown overnight in broth containing 20g/L bactotrypton, lOg/L bacto-yeast extract, 5g/L NaCl (20-10-5 broth) and supplemented with lOOμg/ml ampicillin and 25μg/ml kanamycin. Cultures were diluted down to O.D.600 of 0.1, then grown at 30°C to O.D.600 of 0.6 to 0.8, after which IPTG was added to a final concentration of lmM. At post-induction 2 to 3 hours, the cells were harvested by pelleting, and the cell pellets were washed with lOOmM Tris, pH 7.5. Cell lysates were prepared as follows: to each ml equivalent of pelleted fermentation broth was added 50μl sonication buffer (50mM sodium phosphate, pH 7.8, 0.3M NaCl) with lmg/ml lysozyme; cell suspension was placed on ice for 30 min. Suspension was then brought to a final concentration of 0.2% Tween-20, lOmM dithiothreitol (DTT), and sonicated until cell breakage was complete. Insoluble material was pelleted at 12,000 x g in a microcentrifuge for 15 minutes, the soluble portion was removed to a separate tube and the soluble lysate was then brought to a final concentration of 10% glycerol. Soluble lysates from cells expressing the plasmids produce strongly immunoreactive bands of the predicted molecular weight. Soluble lysates prepared for Ni2+ column purification were prepared with lOmM β-mercaptoethanol (BME) instead of DTT. Lysates were stored at -80°C .
Purification using Ni2+-Nitrosyl acetic acid (NTA) agarose (QIAGEN)
The proteins were then purified by placing the extracted lysate on an NTA agarose column. NTA agarose column chromatography was used because the histidine tag which was fused to the N-terminus of the proteases readily binds to the nickel column. This produces a powerful affinity chromatographic technique for rapidly purifying the soluble protease. The column chromatography was performed in a batch mode. The Ni2+ NTA resin (3ml) was washed twice with 50 ml of Buffer A ( 50mM sodium phosphate pH 7.8 containing 10% glycerol, 0.2% Tween- 20, lOmM BME). The lysate obtained from a 250 ml fermentation (12.5 ml) was incubated with the resin for one hour at 4°C. The flow through was collected by centrifugation. The resin was packed into a 1.0 x 4 cm column and washed with buffer A until the baseline was reached. The bound protein was then eluted with a 20 ml gradient of imidazole (0- 0.5M) in buffer A. Eluted fractions were evaluated by SDS-PAGE and western blot analysis using a rabbit polyclonal antibody to His-HrV 183.
Purification using POROS metal-chelate affinity column
In an alternative method to purify the proteins the lysate containing the proteins were applied to a POROS metal-chelate affinity column. Perfusion chromatography was performed on a POROS MC metal chelate column (4.6 x 50mm, 1.7 ml) precharged with Ni2+. The sample was applied at 10 ml/min and the column was washed with buffer A. The column was step eluted with ten column volumes of buffer A containing 25 mM imidazole. The column was further eluted with a 25 column volume gradient of 25-250 mM imidazole in buffer A. All eluted fractions were evaluated by SDS-PAGE and western blot analysis using rabbit polyclonal antibody.
Example 5
Peptide Synthesis of the 5A/5B and 4B/5A Substrates The peptides 5A/5B and 4B/5A substrates (SEQ ID NOs 16, 18, 19, 20 and 21) were synthesized using Fmoc chemistry on an ABI model 431 A peptide synthesizer. The manufacture recommended FastMoc™ activation strategy (HBTU/HOBt) was used for the synthesis of 4A activator peptide. A more powerful activator, HATU with or without the additive HO At were employed to assemble 5A/5B substrate peptides on a preloaded Wang resin. The peptides were cleaved off the resin and deprotected by standard TFA cleavage protocol. The peptides were purified on reverse phase HPLC and confirmed by mass spectrometric analysis.
Example 6
HPLC-assay using a synthetic 5A/5B peptide substrate
To test the proteolytic activity of the HCV NS3 protease the DTEDWCC SMSYTWTGK (SEQ ID NO 16) and soluble HCV NS3 (SEQ ID NO 27) were placed together in an assay buffer. The assay buffer was 50mM sodium phosphate pH 7.8, containing 15% glycerol, lOmM DTT, 0.2% Tween20 and 200 mM NaCl). The protease activity of SEQ ID NO 27 cleaved the substrate into two byproduct peptides, namely 5A and 5B. The substrate and two byproduct peptides were separated on a reversed- phase HPLC column. (Dynamax, 4.6 x 250 mm) with a pore size of 30θA and a particle size of 5μm. The column was equilibrated with 0.1%TFA (Solvent A) at a flow rate of 1 ml per minute. The substrate and the product peptide standards were applied to the column equilibrated in A. Elution was performed with a acetonitrile gradient (Solvent B=100% acetonitrile in A). Two gradients were used for elution (5% to 70%B in 50 minutes followed by 70% to 100%B in 10 minutes). SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Schering Corp.
(ii) TITLE OF INVENTION: Synthetic Inhibitors of Hepatitis C Virus NS3 Protease
(iii) NUMBER OF SEQUENCES: 30
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Schering Corp.
(B) STREET: 2000 Galloping Hill Road (C) CΓTY: Kenilworth
(D) STATE: New Jersey
(E) COUNTRY: USA (F) ZIP: 07033-0530
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: Apple Macintosh
(C) OPERATING SYSTEM: Macintosh 7.1
(D) SOFTWARE: Microsoft Word 5.1a
(vi) CURRENT APPLICATION DATA:
(A) APPLICAΗON NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICAΗON DATA:
(A) APPLICATION NUMBER: 08/644,544
(B) FILING DATE: 10 May 1996
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Dulak, Norman C.
(B) REGISTRATION NUMBER: 31,608 (C) REFERENCE/DOCKET NUMBER: JB0595
(ix) TELECOMMUNICATION INFORMAΗON:
(A) TELEPHONE: 908-298-5061 (B) TELEFAX: 908-298-5388
(2) INFORMAΗON FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME/KEY:
Glu Asp Val Val Cys Cys Acp Acp Cys Val Val He Val Gly Arg
5 10 15
He Val Leu Ser Gly Lys 20
(2) INFORMAΗON FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY: Glu Asp Val Val Cys Cys Acp Cys Val Val He Val Gly Arg He 5 10 15
Val Leu Ser Gly Lys Lys 20
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 (B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME/KEY:
Glu Asp Val Val Cys Cys Acp Lys Lys Gly Ser Leu Val He Arg 5 10 15
Gly-Val-He-Val-Val-Cys 20
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME/KEY:
(B) OTHER INFORMATION: Xaa is lysine having a peptide bond between its ε-amino group and the carboxyl group of lysine at position 8. The carboxyl group of the Xaa forms a peptide bond with the α-amino group of another lysine (not shown);
Glu Asp Val Val Cys Cys Xaa Lys Gly Ser Leu Val He Arg Gly 5 10 15
Val He Val Val Cys 20
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME/KEY:
(B) OTHER INFORMATION: Amino acid residues at positions 9-21 are preferably D-amino acid residues;
Glu Asp Val Val Cys Cys Acp Acp Lys Gly Ser Leu Val He Arg 5 10 15 Gly Val He Val Val Cys
20
(2) INFORMAΗON FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME/KEY:
(B) OTHER INFORMATION: The lysine residue at position 8 has a peptide bond between the carboxyl group of Acp and the a amino group of the lysine, and the ε amino group of the lysine at position 8 forms a peptide bond with the carboxyl group of the cysteine residue at position 9 and the amino acid residues at positions 9-21 are preferably D-amino acid residues;
Glu Asp Val Val Cys Cys Acp Lys Cys Val Val He Val Gly Arg 5 10 15
He Val Leu Ser Gly Lys 20
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME /KEY:
(B) OTHER INFORMATION: Amino acids at positions 8-20 are preferably D-amino acids.
Glu Asp Val Val Cys Cys Acp Lys Gly Ser Leu Val He Arg Gly 5 10 15
Val He Val Val Cys Lys 20
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME /KEY: (B) OTHER INFORMATION: Xaa is a lysine wherein the ε amino group of which forms a peptide bond with the carboxyl group of the cysteine residue at position 8 and the carboxyl group of the lysine residue forms a peptide bond with an α amino group of another lysine residue (not shown), preferably the amino acid residues at positions 8 - 20 are D- amino acid residues.
Glu Asp Val Val Cys Cys Xaa Cys Val Val He Val Gly Arg He
5 10 15
Val Leu Ser Gly Lys 20
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 14 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE:
(A) NAME/KEY:
(B) OTHER INFORMAΗON: The amino acid residues at positions 1- 13 are preferably D-amino acid residues and lysine at position 14 is preferably an L-amino acid residue;
Lys Gly Ser Leu Val He Arg Gly Val He Val Val Cys Lys
5 10 (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME/KEY:
(B) OTHER INFORMATION: Amino acid residues at positions 1 11 are preferably D-amino acids;
Lys Gly Ser Leu Val He Arg Gly Val He Val Lys 5 10
INFORMATION FOR SEQ ID NO:ll:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME /KEY:
(B) OTHER INFORMATION: The amino acid residues are preferably D-amino acid residues.
Cys Val Val He Val Gly Arg He Val Leu Ser Gly
INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME /KEY:
(B) OTHER INFORMATION: The amino acid residues are preferably D-amino acids and the serine residue at position 1 is preferably acetylated;
Ser-Leu-Val-Ile-Arg-Gly-Val-Ile-Val
5
INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME /KEY: (B) OTHER INFORMATION: The amino acid residues are preferably D-amino acid residues and the lysine residue at position 1 is preferably acetylated.
Lys Gly Ser Leu Val He Arg Gly Val He Val Val Cys 5 10
INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME/KEY:
(B) OTHER INFORMATION: Xaa is biotin and the amino acid residues at positions 2 - 14 are preferably D-amino acids;
Xaa Lys Gly Ser Leu Val He Arg Gly Val He Val Val Cys Lys 5 10
Lys
INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: (D) TOPOLOGY:
(ii) MOLECULE TYPE: peptide
(ix) FEATURE: (A) NAME /KEY: (B) OTHER INFORMATION: Xaa is a lysine residue in which the ε amino group of the lysine forms a peptide bond with a biotin and amino acid residues at positions 1 - 13 are preferably D-amino acid residues.
Lys Gly Ser Leu Val He Arg Gly Val He Val Val Cys Xaa Lys 5 10 15
(2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 549 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE: (A) NAME/KEY: HCV NS3 Protease
GCG CCC ATC ACG GCG TAC GCC CAG CAG ACG AGA GGC CTC CTA GGG 45 Ala Pro He Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly 1 5 10 15
TGT ATA ATC ACC AGC CTG ACT GGC CGG GAC AAA AAC CAA GTG GAG 90 Cys He He Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu 20 25 30
GGT GAG GTC CAG ATC GTG TCA ACT GCT ACC CAA ACC TTC CTG GCA 135 Gly Glu Val Gin He Val Ser Thr Ala Thr Gin Thr Phe Leu Ala 35 40 45
ACG TGC ATC AAT GGG GTA TGC TGG ACT GTC TAC CAC GGG GCC GGA 180 Thr Cys He Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly 50 55 60
ACG AGG ACC ATC GCA TCA CCC AAG GGT CCT GTC ATC CAG ATG TAT 225 Thr Arg Thr He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr
65 70 75
ACC AAT GTG GAC CAA GAC CTT GTG GGC TGG CCC GCT CCT CAA GGT 270 Thr Asn Val Asp Gin Asp Leu Val Gly Trp Pro Ala Pro Gin Gly 80 85 90
TCC CGC TCA TTG ACA CCC TGC ACC TGC GGC TCC TCG GAC CTT TAC 315 Ser Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr 95 100 105
CTG GTT ACG AGG CAC GCC GAC GTC ATT CCC GTG CGC CGG CGA GGT 360
Leu Val Thr Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly 110 115 120
GAT AGC AGG GGT AGC CTG CTT TCG CCC CGG CCC ATT TCC TAC CTA 405
Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu
125 130 135
AAA GGC TCC TCG GGG GGT CCG CTG TTG TGC CCC GCG GGA CAC GCC 450
Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala 140 145 150
GTG GGC CTA TTC AGG GCC GCG GTG TGC ACC CGT GGA GTG ACC AAG 495
Val Gly Leu Phe Arg Ala Ala Val Cys Thr Arg Gly Val Thr Lys 155 160 165
GCG GTG GAC TTT ATC CCT GTG GAG AAC CTA GAG ACA ACC ATG AGA 540 Ala Val Asp Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg
170 175 180
TCC CCG GTG Ser Pro Val
(2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 162 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: NS4A AGC ACC TGG GTG CTC GTT GGC GGC GTC CTG GCT GCT CTG GCC GCG 45 Ser Thr Trp Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala 1 5 10 15
TAT TGC CTG TCA ACA GGC TGC GTG GTC ATA GTG GGC AGG ATT GTC 90 Tyr Cys Leu Ser Thr Gly Cys Val Val He Val Gly Arg He Val 20 25 30
TTG TCC GGG AAG CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC 135 Leu Ser Gly Lys Pro Ala He He Pro Asp Arg Glu Val Leu Tyr
35 40 45
CAG GAG TTC GAT GAG ATG GAA GAG TGC 162 Gin Glu Phe Asp Glu Met Glu Glu Cys 50
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double (D) TOPOLOGY: double
(ii) MOLECULE TYPE: cDNA
GA TCA CCG GTC TAG ATCT T GGC CAG ATC TAGA
(2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid (C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY:
CCG GTC CGG AAG AAA AAG AGA CGC TAG C AG GCC TTC TTT TTC TCT GCG ATC G
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 79 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE: (A) NAME /KEY: CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC CAG GAA TTC GT TAA TAT GGA CTG TCC CTC CAA GAG ATG GTC CTT AAG
GAT GAG ATG GAA GAG TGC CGG AAG AAA AAG AGA CGC A
CTA CTC TAC CTT CTC ACG GCC TTC TTT TTC TCT GCG TTC GA
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE:
(A) NAME /KEY: NS4A Active Mutant Cys Val Val He Val Gly Arg He Val Leu Ser Gly Lys 5 10
(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE: (A) NAME/KEY: Soluble 5A/5B Substrate
Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr
5 10 15
Gly Lys
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 810 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: pNB182Δ4AHT
ATG AGA GGA TCG CAT CAC CAT CAC CAT CAC ACG GAT CCG CCC ATC 45 Met Arg Gly Ser His His His His His His Thr Asp Pro Pro He 1 5 10 15 ACG GCG TAC GCC CAG CAG ACG AGA GGC CTC CTA GGG TGT ATA ATC 90 Thr Ala Tyr Ala Gin Gin Thr Arg Gly Leu Leu Gly Cys He He 20 25 30
ACC AGC CTG ACT GGC CGG GAC AAA AAC CAA GTG GAG GGT GAG GTC 135 Thr Ser Leu Thr Gly Arg Asp Lys Asn Gin Val Glu Gly Glu Val 35 40 45
CAG ATC GTG TCA ACT GCT ACC CAA ACC TTC CTG GCA ACG TGC ATC 180 Gin He Val Ser Thr Ala Thr Gin Thr Phe Leu Ala Thr Cys He
50 55 60
AAT GGG GTA TGC TGG ACT GTC TAC CAC GGG GCC GGA ACG AGG ACC 225 Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Thr Arg Thr
65 70 75
ATC GCA TCA CCC AAG GGT CCT GTC ATC CAG ATG TAT ACC AAT GTG 270 He Ala Ser Pro Lys Gly Pro Val He Gin Met Tyr Thr Asn Val 80 85 90
GAC CAA GAC CTT GTG GGC TGG CCC GCT CCT CAA GGT TCC CGC TCA 315 Asp Gin Asp Leu Val Gly Trp Pro Ala Pro Gin Gly Ser Arg Ser 95 100 105
TTG ACA CCC TGC ACC TGC GGC TCC TCG GAC CTT TAC CTG GTT ACG 360 Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr
110 115 120
AGG CAC GCC GAC GTC ATT CCC GTG CGC CGG CGA GGT GAT AGC AGG 405 Arg His Ala Asp Val He Pro Val Arg Arg Arg Gly Asp Ser Arg 125 130 135 GGT AGC CTG CTT TCG CCC CGG CCC ATT TCC TAC CTA AAA GGC TCC 450
Gly Ser Leu Leu Ser Pro Arg Pro He Ser Tyr Leu Lys Gly Ser 140 145 150
TCG GGG GGT CCG CTG TTG TGC CCC GCG GGA CAC GCC GTG GGC CTA 495
Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly Leu 155 160 165
TTC AGG GCC GCG GTG TGC ACC CGT GGA GTG ACC AAG GCG GTG GAC 540 Phe Arg Ala Ala Val Cys Thr Arg Gly Val Thr Lys Ala Val Asp
170 175 180
TTT ATC CCT GTG GAG AAC CTA GAG ACA ACC ATG AGA TCC CCG GGG 585
Phe He Pro Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Gly 185 190 195
GTG CTC GTT GGC GGC GTC CTG GCT GCT CTG GCC GCG TAT TGC CTG 630
Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu 200 205 210
TCA ACA GGC TGC GTG GTC ATA GTG GGC AGG ATT GTC TTG TCC GGG 720
Ser Thr Gly Cys Val Val He Val Gly Arg He Val Leu Ser Gly 215 220 225
AAG CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC CAG GAG TTC 765
Lys Pro Ala He He Pro Asp Arg Glu Val Leu Tyr Gin Glu Phe 230 235 240
GAT GAG ATG GAA GAG TGC CGG AAG AAA AAG AGA CGC AAG CTT AAT 810 Asp Glu Met Glu Glu Cys Arg Lys Lys Lys Arg Arg Lys Leu Asn
245 250 255
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 162 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(ix) FEATURE:
(A) NAME/KEY: Native NS4A
TCA ACA TGG GTG CTC GTT GGC GGC GTC CTG GCT GCT CTG GCC GCG 45 Ser Thr Trp Val Leu Val Gly Gly Val Leu Ala Ala Leu Ala Ala 1 5 10 15
TAT TGC CTG TCA ACA GGC TGC GTG GTC ATA GTG GGC AGG ATT GTC 90 Tyr Cys Leu Ser Thr Gly Cys Val Val He Val Gly Arg He Val 20 25 30
TTG TCC GGG AAG CCG GCA ATT ATA CCT GAC AGG GAG GTT CTC TAC 135 Leu Ser Gly Lys Pro Ala He He Pro Asp Arg Glu Val Leu Tyr 35 40 45
CAG GAG TTC GAT GAG ATG GAA GAG TGC Gin Glu Phe Asp Glu Met Glu Glu Cys 50
2) INFORMAΗON FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE: (A) NAME/KEY: Native 5A/5B Substrate Asp Thr Glu Asp Val Val Cys Cys Ser Met Ser Tyr Thr Trp Thr
5 10 15
Gly
2) INFORMAΗON FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS:
(D) TOPOLOGY:
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE:
(A) NAME/KEY: NS3/NS4A Cleavage site
Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu 5 10 15 Val Gly Gly Val Leu
20
2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE:
(A) NAME/KEY: NS4A/4B Cleavage Site Tyr Gin Glu Phe Asp Glu Met Glu Glu Cys Ser Gin His Leu Pro
5 10 15
Tyr He Glu Gin Gly 20 2) INFORMAΗON FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE:
(A) NAME/KEY: 4B/5A
Trp He Ser Ser Glu Cys Thr Thr Pro Cys Ser Gly Ser Trp Leu
5 10 15
Arg Asp He Trp Asp 20
2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE:
(A) NAME/KEY:
Glu-Asp-Val-Val-Cys-Cys-Acp-Lys 5
2) INFORMAΗON FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: polypeptide
(ix) FEATURE: (A) NAME/KEY:
Cys-Val-Val-Ile-Val-Gly-Arg-He-Val-Leu-Ser-Gly-Lys 5 10

Claims

WE CLAIM:
1. A bivalent inhibitor of an hepatitis C NS3 protease comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence of a hepatitis C NS4A polypeptide.
2. The bivalent inhibitor of claim 1 selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
3. An inhibitor of an HCV protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.
4. An inhibitor of claim 3 selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.
5. An inhibitor of an HCV NS3 protease comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full- length sequence of an HCV NS4A polypeptide.
6. The use of an inhibitor of an HCV NS3 protease for the manufacture of a medicament for treating hepatitis C, wherein the inhibitor is comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full- length sequence of a hepatitis C NS4A polypeptide.
7. The use of claim 6 wherein the inhibitor is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4,
SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
8. The use of an inhibitor of an HCV NS3 protease for the manufacture of a medicament for treating hepatitis C, wherein the inhibitor is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.
9. The use of claim 8 wherein the inhibitor is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.
10. The use of an inhibitor of an HCV NS3 protease for the manufacture of a medicament for treating hepatitis C, wherein the inhibitor is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length subsequence of an HCV NS4A polypeptide.
11. A pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being an inhibitor of an HCV NS3 protease, said inhibitor being comprised of a first peptide linked to a second peptide, said first peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the hepatitis C NS3 protease and said second peptide being a subsequence, a mutated subsequence or a mutated full-length sequence of a hepatitis C NS4A polypeptide, and a pharmaceutical carrier.
12. The pharmaceutical composition of claim 11 wherein the inhibitor is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
13. A pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, said inhibitor being a subsequence, a mutated subsequence or a mutated full-length sequence of a substrate of the HCV NS3 protease.
14. The pharmaceutical composition of claim 13 wherein the inhibitor is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15.
15. A pharmaceutical composition for treating an individual infected with hepatitis C virus, said pharmaceutical composition being comprised of an inhibitor of an HCV NS3 protease and a pharmaceutical carrier, wherein said inhibitor is comprised of a peptide, said peptide being a subsequence, a mutated subsequence or a mutated full-length subsequence of an HCV NS4A polypeptide.
EP97923563A 1996-05-10 1997-05-08 Synthetic inhibitors of hepatitis c virus ns3 protease Withdrawn EP0907659A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64454496A 1996-05-10 1996-05-10
US644544 1996-05-10
PCT/US1997/007632 WO1997043310A1 (en) 1996-05-10 1997-05-08 Synthetic inhibitors of hepatitis c virus ns3 protease

Publications (1)

Publication Number Publication Date
EP0907659A1 true EP0907659A1 (en) 1999-04-14

Family

ID=24585361

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97923563A Withdrawn EP0907659A1 (en) 1996-05-10 1997-05-08 Synthetic inhibitors of hepatitis c virus ns3 protease

Country Status (5)

Country Link
EP (1) EP0907659A1 (en)
JP (1) JPH11513890A (en)
AU (1) AU2933797A (en)
CA (1) CA2254122A1 (en)
WO (1) WO1997043310A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299134B1 (en) * 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio PROCEDURE FOR THE PRODUCTION OF PEPTIDES WITH PROTEAS INHIBITING THE NS3 PROTEASIS OF THE HCV VIRUS, PEPTIDES SO OBTAINABLE AND PEPTIDES
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AU1324300A (en) * 1998-10-26 2000-05-15 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
WO2003006490A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
CU23245A1 (en) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CHEMICAL CODING CHAINS FOR INDUCTIVE PROTEINS OF VIRUS EFFECTS. PREPARED USING CHEMICAL PROTEINS
US7241796B2 (en) 2001-10-24 2007-07-10 Vertex Pharmaceuticals Inc. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
NZ561851A (en) 2002-04-11 2009-05-31 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 - NS4 protease
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
ES2315568T3 (en) 2002-05-20 2009-04-01 Bristol-Myers Squibb Company HEPATITIS C VIRUS INHIBITORS BASED ON P1 'CYCLALKYL SUBSTITUTED.
ATE481106T1 (en) 2002-05-20 2010-10-15 Bristol Myers Squibb Co HETEROCYCLIC SULFONAMIDE HEPATITIS C VIRUS INHIBITORS
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
DK1654261T3 (en) 2003-05-21 2008-01-14 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
AR045596A1 (en) 2003-09-05 2005-11-02 Vertex Pharma INHIBITORS OF SERINE PROTEASES IN PARTICULAR HCV PROTEASA NS3-NS4A
WO2005028501A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
KR20060130027A (en) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
BRPI0415373A (en) 2003-10-14 2006-12-12 Intermune Inc macrocyclic carboxylic acids and acylsulfonamides as hcv replication inhibitors
JP4890254B2 (en) 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド HCVNS3-NS4A protease resistant mutant
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
US7683033B2 (en) 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
SI1719773T1 (en) 2004-02-24 2009-08-31 Japan Tobacco Inc Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
ATE512971T1 (en) 2004-07-20 2011-07-15 Boehringer Ingelheim Int PEPTIDE ANALOGUES AS HEPATITIS C INHIBITORS
US20080267915A1 (en) 2004-10-01 2008-10-30 Vertex Pharmaceuticals Hcv Ns3-Ns4a Protease Inhibition
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
AU2006276246B2 (en) 2005-07-25 2012-09-27 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
US20070105781A1 (en) 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
SI2194043T1 (en) 2005-08-19 2014-04-30 Vertex Pharmaceuticals Incorporated Processes
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CU23578A1 (en) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech VIRUS CAPSID PROTEIN DENGES INDUCTIVE PROTECTION RESPONSE AND VACCINE COMPOSITION
CN101415705B (en) 2005-10-11 2011-10-26 因特蒙公司 Compounds and methods for inhibiting hepatitis c viral replication
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
EP2392590A3 (en) 2005-11-11 2012-03-14 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CU23630A1 (en) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech CHEMERIC PEPTIDE MOLECULES WITH ANTIVIRAL PROPERTIES AGAINST VIRUSES OF THE FLAVIVIRIDAE FAMILY
CN101815533A (en) 2007-05-04 2010-08-25 弗特克斯药品有限公司 Be used for the treatment of the combined therapy that HCV infects
EA025794B1 (en) 2007-06-29 2017-01-30 Джилид Сайэнс, Инк. Antiviral compounds
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
JP5702388B2 (en) 2009-09-15 2015-04-15 タイゲン バイオテクノロジー カンパニー，リミテッド HCV protease inhibitor
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
FR2987836A1 (en) * 2012-03-09 2013-09-13 Biomerieux Sa INTERFERENCE PEPTIDES AND METHOD FOR DETECTING MICROORGANISMS
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272179B (en) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
EP0824596A1 (en) * 1995-05-12 1998-02-25 Schering Corporation Surface plasmon resonance based enzymatic assay
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9743310A1 *

Also Published As

Publication number Publication date
AU2933797A (en) 1997-12-05
CA2254122A1 (en) 1997-11-20
JPH11513890A (en) 1999-11-30
WO1997043310A1 (en) 1997-11-20

Similar Documents

Publication Publication Date Title
US5990276A (en) Synthetic inhibitors of hepatitis C virus NS3 protease
EP0907659A1 (en) Synthetic inhibitors of hepatitis c virus ns3 protease
WO1997043310A9 (en) Synthetic inhibitors of hepatitis c virus ns3 protease
US5843752A (en) Soluble active hepatitis C virus protease
US6653127B1 (en) Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
AU764589B2 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
JP2002509075A (en) Peptide inhibitors of serine protease activity related to the NS3 protein of HCV, related uses and methods of making the same
WO1995022985A1 (en) Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)
Butkiewicz et al. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity
CA2220729C (en) Method for refolding insoluble aggregates of hepatitis c virus protease
US6251583B1 (en) Peptide substrates for HCV NS3 protease assays
US5767233A (en) Soluble cleavable substrates of the hepatitis C virus protease
RU2451026C2 (en) Chimeric peptide molecules with antiviral properties with respect to viruses family flaviviridae
EP0846164B1 (en) Method for assaying in vitro the proteolytic activity of polypeptides having hcv ns3 protease activity and peptide substrates to be used in this method.
ES2273934T5 (en) ANTIGEN OF HEPATITIS VIRUS NO A, NO B, DIAGNOSTIC METHODS AND VACCINES.
MXPA97008679A (en) Dissociable, soluble substrates of the hepatiti virus protease
Libby et al. Human rhinovirus 3C protease: cloning and expression of an active form in Escherichia coli
MXPA98009330A (en)
KR19980069020A (en) Histidine-labeled Korean non-structural protein 3-4A and its preparation method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 981029;LV PAYMENT 981029;RO PAYMENT 981029

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011201